多西他赛加雷莫芦单抗二线治疗在化疗免疫治疗后的非小细胞肺癌患者中的影响：一项回顾性研究。

Impact of docetaxel plus ramucirumab in a second-line setting after chemoimmunotherapy in patients with non-small-cell lung cancer: A retrospective study.

机构信息

Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.

出版信息

Thorac Cancer. 2022 Jan;13(2):173-181. doi: 10.1111/1759-7714.14236. Epub 2021 Nov 17.

DOI:10.1111/1759-7714.14236

PMID:34791812

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8758423/

Abstract

BACKGROUND

Chemoimmunotherapy has become a standard treatment option for patients with untreated advanced non-small-cell lung cancer (NSCLC). However, numerous patients with advanced NSCLC develop disease progression. Therefore, the selection of second-line treatment after chemoimmunotherapy is crucial for improving clinical outcomes.

METHODS

Of 88 enrolled patients with advanced NSCLC who received chemoimmunotherapy, we retrospectively evaluated 33 who received second-line chemotherapy after progression of chemoimmunotherapy at six centers in Japan. Among them, 18 patients received docetaxel plus ramucirumab and 15 patients received single-agent chemotherapy.

RESULTS

The objective response rate in patients treated with docetaxel plus ramucirumab was significantly higher than that in patients treated with a single-agent chemotherapy regimen (55.6% vs. 0%, p < 0.001). The median progression-free survival (PFS) of patients who received docetaxel plus ramucirumab and single-agent chemotherapy was 5.8 months and 5.0 months, respectively (log-rank test p = 0.17). In the docetaxel plus ramucirumab regimen group, patients who responded to chemoimmunotherapy for ≥8.8 months had a significantly longer response to docetaxel plus ramucirumab than those who responded for <8.8 months (not reached vs. 4.1 months, log-rank test p = 0.003). In contrast, in the single-agent chemotherapy group, there was no significant difference in PFS between the ≥8.8- and <8.8-month PFS groups with chemoimmunotherapy (5.0 vs. 1.6 months, log-rank test p = 0.66).

CONCLUSION

Our retrospective observations suggest that the group with longer PFS with chemoimmunotherapy might be expected to benefit from docetaxel plus ramucirumab treatment in second-line settings for patients with advanced NSCLC.

摘要

背景

化疗免疫治疗已成为未经治疗的晚期非小细胞肺癌（NSCLC）患者的标准治疗选择。然而，许多晚期 NSCLC 患者会出现疾病进展。因此，化疗免疫治疗后二线治疗的选择对于改善临床结局至关重要。

方法

我们回顾性评估了 88 例在日本 6 个中心接受化疗免疫治疗后疾病进展的晚期 NSCLC 患者中的 33 例接受二线化疗的患者。其中 18 例接受多西他赛加雷莫芦单抗治疗，15 例接受单药化疗。

结果

多西他赛加雷莫芦单抗治疗组的客观缓解率明显高于单药化疗组（55.6% vs. 0%，p<0.001）。多西他赛加雷莫芦单抗和单药化疗组的中位无进展生存期（PFS）分别为 5.8 个月和 5.0 个月（对数秩检验 p=0.17）。在多西他赛加雷莫芦单抗组中，对化疗免疫治疗反应≥8.8 个月的患者对多西他赛加雷莫芦单抗的反应明显长于反应<8.8 个月的患者（未达到 vs. 4.1 个月，对数秩检验 p=0.003）。相比之下，在单药化疗组中，化疗免疫治疗 PFS≥8.8 个月和<8.8 个月的患者的 PFS 无显著差异（5.0 个月 vs. 1.6 个月，对数秩检验 p=0.66）。